A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Trial Profile

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ALTIC
  • Most Recent Events

    • 02 Nov 2017 Primary endpoint (platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover) has been met, as per results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 02 Nov 2017 Results comparing low dose ticagrelor platelet reactivity to standard dose of clopidogrel, presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 13 Jul 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top